Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 8.55 USD 3.76% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
Iovance Biotherapeutics Inc?
Write Note

Iovance Biotherapeutics Inc
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Iovance Biotherapeutics Inc
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Net Income
-$410m
CAGR 3-Years
-10%
CAGR 5-Years
-20%
CAGR 10-Years
-36%
Abbvie Inc
NYSE:ABBV
Net Income
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Income
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
5%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Iovance Biotherapeutics Inc
Glance View

Market Cap
2.6B USD
Industry
Biotechnology

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 319 full-time employees. The company went IPO on 2008-06-20. The firm is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The company has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer (NSCLC). In addition, the Company is investigating the combinations of TIL therapy with immune checkpoint inhibitors (ICIs) in metastatic melanoma, cervical cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). The company is investigating peripheral blood lymphocyte (PBL) therapy for patients with refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

IOVA Intrinsic Value
13.26 USD
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Iovance Biotherapeutics Inc's Net Income?
Net Income
-410m USD

Based on the financial report for Sep 30, 2024, Iovance Biotherapeutics Inc's Net Income amounts to -410m USD.

What is Iovance Biotherapeutics Inc's Net Income growth rate?
Net Income CAGR 10Y
-36%

Over the last year, the Net Income growth was 5%. The average annual Net Income growth rates for Iovance Biotherapeutics Inc have been -10% over the past three years , -20% over the past five years , and -36% over the past ten years .

Back to Top